Literature DB >> 28645460

Associations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy.

Sunkyung Kim1, Yong Zhu2, Paul A Romitti2, Deborah J Fox3, Daniel W Sheehan4, Rodolfo Valdez5, Dennis Matthews6, Brent J Barber7.   

Abstract

The long-term efficacy of corticosteroid treatment and timing of treatment initiation among Duchenne muscular dystrophy (DMD) patients is not well-understood. We used data from a longitudinal, population-based DMD surveillance program to examine associations between timing of treatment initiation (early childhood [before or at age 5 years], late childhood [after age 5 years], and naïve [not treated]) and five clinical outcomes (age at loss of ambulation; ages at onset of cardiomyopathy, scoliosis, and first fracture; and pulmonary function). Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using survival analysis. DMD patients who initiated corticosteroid treatment in early childhood had a higher risk of earlier onset cardiomyopathy compared to cases who initiated treatment in late childhood (HR = 2.0, 95% CI = [1.2, 3.4]) or treatment naïve patients (HR = 1.9, 95% CI = [1.1, 3.2]), and higher risk of suffering a fracture (HR = 2.3, 95% CI = [1.4, 3.7] and HR = 2.6, 95% CI = [1.6, 4.2], respectively). Patients with early childhood treatment had slightly decreased respiratory function compared with those with late childhood treatment. Ages at loss of ambulation or scoliosis diagnosis did not differ statistically among treatment groups. We caution that the results from our study are subject to several limitations, as they were based on data abstracted from medical records. Further investigations using improved reporting of disease onset and outcomes are warranted to obtain a more definitive assessment of the association between the timing of corticosteroid treatment and disease severity. Published by Elsevier B.V.

Entities:  

Keywords:  Ambulation; Cardiomyopathy; Corticosteroid; Duchenne muscular dystrophy; Fractures; Pulmonary function; Scoliosis

Mesh:

Substances:

Year:  2017        PMID: 28645460      PMCID: PMC5824693          DOI: 10.1016/j.nmd.2017.05.019

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  44 in total

1.  Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Neuromuscul Disord       Date:  2008-12-12       Impact factor: 4.296

2.  Are corticosteroids effective in Duchenne muscular dystrophy.

Authors:  Dheeraj Shah
Journal:  Indian Pediatr       Date:  2008-05       Impact factor: 1.411

3.  Steroid therapy and cardiac function in Duchenne muscular dystrophy.

Authors:  L W Markham; R L Spicer; P R Khoury; B L Wong; K D Mathews; L H Cripe
Journal:  Pediatr Cardiol       Date:  2005 Nov-Dec       Impact factor: 1.655

4.  Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy.

Authors:  Denis Duboc; Christophe Meune; Guy Lerebours; Jean-Yves Devaux; Guy Vaksmann; Henri-Marc Bécane
Journal:  J Am Coll Cardiol       Date:  2005-03-15       Impact factor: 24.094

5.  The muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology.

Authors:  Lisa A Miller; Paul A Romitti; Christopher Cunniff; Charlotte Druschel; Katherine D Mathews; F John Meaney; Dennis Matthews; Jiji Kantamneni; Zhen-Fang Feng; Nancy Zemblidge; Timothy M Miller; Jennifer Andrews; Deborah Fox; Emma Ciafaloni; Shree Pandya; April Montgomery; Aileen Kenneson
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2006-11

6.  An effective, low-dosage, intermittent schedule of prednisolone in the long-term treatment of early cases of Duchenne dystrophy.

Authors:  Maria Kinali; Eugenio Mercuri; Marion Main; Francesco Muntoni; Victor Dubowitz
Journal:  Neuromuscul Disord       Date:  2002-10       Impact factor: 4.296

7.  Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy.

Authors:  W M King; R Ruttencutter; H N Nagaraja; V Matkovic; J Landoll; C Hoyle; J R Mendell; J T Kissel
Journal:  Neurology       Date:  2007-05-08       Impact factor: 9.910

8.  Remission of clinical signs in early duchenne muscular dystrophy on intermittent low-dosage prednisolone therapy.

Authors:  V Dubowitz; M Kinali; M Main; E Mercuri; F Muntoni
Journal:  Eur J Paediatr Neurol       Date:  2002       Impact factor: 3.140

Review 9.  Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology.

Authors:  David Gloss; Richard T Moxley; Stephen Ashwal; Maryam Oskoui
Journal:  Neurology       Date:  2016-02-02       Impact factor: 9.910

Review 10.  Glucocorticoid corticosteroids for Duchenne muscular dystrophy.

Authors:  A Y Manzur; T Kuntzer; M Pike; A Swan
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23
View more
  12 in total

1.  Disease-modifying bioactivity of intravenous cardiosphere-derived cells and exosomes in mdx mice.

Authors:  Russell G Rogers; Mario Fournier; Lizbeth Sanchez; Ahmed G Ibrahim; Mark A Aminzadeh; Michael I Lewis; Eduardo Marbán
Journal:  JCI Insight       Date:  2019-04-04

2.  Risk Factors for Cardiac and Non-cardiac Causes of Death in Males with Duchenne Muscular Dystrophy.

Authors:  Carol A Wittlieb-Weber; Kenneth R Knecht; Chet R Villa; Chentel Cunningham; Jennifer Conway; Matthew J Bock; Katheryn E Gambetta; Ashwin K Lal; Kurt R Schumacher; Sabrina P Law; Shriprasad R Deshpande; Shawn C West; Joshua M Friedland-Little; Irene D Lytrivi; Michael A McCulloch; Ryan J Butts; David R Weber; Jonathan N Johnson
Journal:  Pediatr Cardiol       Date:  2020-02-03       Impact factor: 1.655

3.  Efficacy of corticosteroid in decreasing scoliosis and extending time to loss of ambulation in a single clinic: an effectiveness trial.

Authors:  Michael D Sussman; Susan E Sienko; Cathleen E Buckon; Coleman Hilton; Camila Bedeschi De Mattos; Charles d'Amato
Journal:  J Child Orthop       Date:  2020-10-01       Impact factor: 1.548

Review 4.  A Review of MD STAR net's Research Contributions to Pediatric-Onset Dystrophinopathy in the United States; 2002-2017.

Authors:  Kashika M Sahay; Tiffany Smith; Kristin M Conway; Paul A Romitti; Molly M Lamb; Jennifer Andrews; Shree Pandya; Joyce Oleszek; Christopher Cunniff; Rodolfo Valdez
Journal:  J Child Neurol       Date:  2018-10-22       Impact factor: 1.987

5.  Simvastatin provides long-term improvement of left ventricular function and prevents cardiac fibrosis in muscular dystrophy.

Authors:  Min J Kim; Kenneth L Bible; Michael Regnier; Marvin E Adams; Stanley C Froehner; Nicholas P Whitehead
Journal:  Physiol Rep       Date:  2019-03

Review 6.  Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?

Authors:  Stephanie Kourakis; Cara A Timpani; Dean G Campelj; Patricia Hafner; Nuri Gueven; Dirk Fischer; Emma Rybalka
Journal:  Orphanet J Rare Dis       Date:  2021-03-04       Impact factor: 4.123

Review 7.  The clinical course of Duchenne muscular dystrophy in the corticosteroid treatment era: a systematic literature review.

Authors:  Shelagh M Szabo; Renna M Salhany; Alison Deighton; Meagan Harwood; Jean Mah; Katherine L Gooch
Journal:  Orphanet J Rare Dis       Date:  2021-05-22       Impact factor: 4.123

8.  Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.

Authors:  Jean K Mah; Paula R Clemens; Michela Guglieri; Edward C Smith; Richard S Finkel; Mar Tulinius; Yoram Nevo; Monique M Ryan; Richard Webster; Diana Castro; Nancy L Kuntz; Craig M McDonald; Jesse M Damsker; Benjamin D Schwartz; Laurel J Mengle-Gaw; Stefan Jackowski; Georgia Stimpson; Deborah A Ridout; Vandana Ayyar-Gupta; Giovanni Baranello; Adnan Y Manzur; Francesco Muntoni; Heather Gordish-Dressman; Mika Leinonen; Leanne M Ward; Eric P Hoffman; Utkarsh J Dang
Journal:  JAMA Netw Open       Date:  2022-01-04

9.  Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dystrophy.

Authors:  Erika Finanger; Krista Vandenborne; Richard S Finkel; H Lee Sweeney; Gihan Tennekoon; Sabrina Yum; Maria Mancini; Pradeep Bista; Andrew Nichols; Hanlan Liu; Angelika Fretzen; Joanne M Donovan
Journal:  J Neuromuscul Dis       Date:  2019

Review 10.  Prognostic indicators of disease progression in Duchenne muscular dystrophy: A literature review and evidence synthesis.

Authors:  Nermina Ferizovic; Jessica Summers; Igor Beitia Ortiz de Zárate; Christian Werner; Joel Jiang; Erik Landfeldt; Katharina Buesch
Journal:  PLoS One       Date:  2022-03-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.